1. Preparation
Abstracts should be prepared strictly according to the following instructions:

- Abstracts must be submitted in English.
- Abstracts must be written in Times New Roman, font size 10.
- Abstracts should have a minimum of 450 and a maximum of 500 words.
- The use of underlined and italics is not permitted. Words that need emphasis should be bold type.
- Abstracts should include:
  - purpose of the study
  - methods used
  - summary of results containing real data and appropriate statistical assessments
  - conclusions
- Abstracts must report on high quality original research in the field of neuropsychopharmacology that has not been published whole or in part elsewhere.
- Abstracts must be relevant to one of the four main topics.
- The statements, in particular in the conclusion section, should be balanced.
- Use standard abbreviations for well established neuropsychopharmaceuticals. Place unusual abbreviations in parentheses after the full word the first time it appears. Clearly identify all neuropsychopharmaceuticals used. Please note that no abbreviations or trade names are allowed in the title. However, the generic name may be used.
- Please select 3 keywords from the list of keywords. A keywords index will be published in the workshop supplement to the journal European Neuropsychopharmacology.
- Only one table is allowed, please note that graphs and pictures cannot be included.
- At least one, but no more than three references to previous publications may be included. In the body text, a publication should be referred to by a consecutive number between brackets, i.e. [1], [2] and [3]. The references should be provided in accordance with the following example: [1] Chamberlain, S.R., Hampshire, A., Muller, U., Rubia, K., Del Campo, N., 2009. Atomoxetine modulates right inferior frontal activation during inhibitory control. A pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65, 550-555.
- A disclosure on potential conflicts of interest is requested when submitting a abstract.

Abstracts should be received before 1 November 2012

2. Evaluation
The abstracts will be evaluated by a scientific review committee. The author will be informed about the decision by e-mail on or before 10 January 2013. This notification will be sent to the e-mail address provided with the abstract submission. Please note that the decision of the scientific review committee is final, there can be no correspondence about the outcome.

When your abstract is accepted you have to give a poster presentation on this abstract at the ECNP Workshop and attend the sessions from Friday morning 09.00 until Sunday 13.05.

In addition, from the accepted abstracts, 20 young scientists will be invited to present their data during one of the main sessions.

3. Publication
The abstracts will be reviewed according to the scientific standard of the journal European Neuropsychopharmacology and all accepted abstracts will be published in a supplement to the journal. The publisher of European Neuropsychopharmacology holds all publication rights including copyright.

After the workshop, ECNP would like to publish a selection of the posters on the ECNP website www.ecnp.eu. The selection is made by a scientific review committee during the poster sessions. For approval to possibly have your poster published, please tick the appropriate box on the abstract submission website.